Full-Time

Senior Research Associate

Cell Therapy Analytics

Posted on 2/7/2024

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops Gene Writing genome engineering technology

Data & Analytics

Senior

Cambridge, MA, USA

Required Skills
Data Analysis
Requirements
  • BS with 5+/MS with 3+ years of experience in Immunology, Immuno-oncology, cell and gene therapy or related field is required.
  • Experience with research and/or manufacturing scale cell and tissue culture techniques with primary cells or established cell lines is required.
  • Experience with cell therapy based unit operations, such as CliniMACS, CliniMACS Prodigy, Rotea, Cue, etc.
  • Experience developing cell based, functional potency assays is a plus.
  • Knowledge and experience with non-viral gene delivery and gene editing.
  • Experience with flow cytometry is preferred.
  • Experience in cell assay development and characterization is a plus.
  • Experience with ELISA/MSD, qPCR, ddPCR, Incucyte, luciferase-based plate readouts and/or high speed cell sorting is a plus.
Responsibilities
  • Support development and production of hematopoietic primary cell banks for use in Cell Therapy, Gene Writing platforms.
  • Support characterization assays to inform the biology and process understanding of Gene Writing.
  • Work collaboratively with process and analytics teams to execute developed analytics to inform in-process phenotypic and functional characterization of gene edited cells.
  • Independently perform and screen new assays for analytical method selection.
  • Assist in interpretation and troubleshooting of analytical assays in various platforms including, flow cytometry, ELISA/MSD, qPCR and ddPCR. Collect and interpret data, prepare experimental reports, and present findings to the IO Process team.
  • Support the development of protocols, test methods, and analytical sampling plans.

Tessera Therapeutics is pioneering Gene Writing™, a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. They are focused on expanding possibilities in genetic medicine through tissue-targeted non-viral delivery technology, addressing major unmet medical needs with potentially curative and accessible therapies.

Company Stage

Series C

Total Funding

$581.7M

Headquarters

Somerville, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

85%
INACTIVE